Avalo Therapeutics, Inc.

NasdaqCM:AVTX Stock Report

Market Cap: US$92.2m

Avalo Therapeutics Management

Management criteria checks 2/4

Avalo Therapeutics' CEO is Garry Neil, appointed in Feb 2022, has a tenure of 2.83 years. total yearly compensation is $1.08M, comprised of 44.2% salary and 55.8% bonuses, including company stock and options. directly owns 0.001% of the company’s shares, worth $525.45. The average tenure of the management team and the board of directors is 2.8 years and 2.8 years respectively.

Key information

Garry Neil

Chief executive officer

US$1.1m

Total compensation

CEO salary percentage44.2%
CEO tenure2.8yrs
CEO ownership0.0006%
Management average tenure2.8yrs
Board average tenure2.8yrs

Recent management updates

Recent updates

Avalo to get ~15M upfront in license deal with Apollo Therapeutics for AVTX-007

Aug 01

Avalo Therapeutics announces one-for-twelve reverse stock split

Jul 06

Is Cerecor (NASDAQ:CERC) A Risky Investment?

Aug 10
Is Cerecor (NASDAQ:CERC) A Risky Investment?

Cerecor enters into $35M debt financing agreement with Horizon Technology Finance

Jun 07

What Kind Of Investors Own Most Of Cerecor Inc. (NASDAQ:CERC)?

Mar 10
What Kind Of Investors Own Most Of Cerecor Inc. (NASDAQ:CERC)?

Have Insiders Been Buying Cerecor Inc. (NASDAQ:CERC) Shares?

Jan 18
Have Insiders Been Buying Cerecor Inc. (NASDAQ:CERC) Shares?

Armistice Capital adds 2.5M Cerecor shares for $6.5M

Jan 13

Cerecor slumps 12% on stock and pre-funded warrants offering

Jan 07

CEO Compensation Analysis

How has Garry Neil's remuneration changed compared to Avalo Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$8m

Jun 30 2024n/an/a

-US$19m

Mar 31 2024n/an/a

-US$49m

Dec 31 2023US$1mUS$475k

-US$32m

Sep 30 2023n/an/a

-US$33m

Jun 30 2023n/an/a

-US$25m

Mar 31 2023n/an/a

-US$30m

Dec 31 2022US$1mUS$469k

-US$42m

Sep 30 2022n/an/a

-US$51m

Jun 30 2022n/an/a

-US$72m

Mar 31 2022n/an/a

-US$76m

Dec 31 2021US$1mUS$423k

-US$84m

Sep 30 2021n/an/a

-US$81m

Jun 30 2021n/an/a

-US$77m

Mar 31 2021n/an/a

-US$73m

Dec 31 2020US$3mUS$373k

-US$64m

Compensation vs Market: Garry's total compensation ($USD1.08M) is above average for companies of similar size in the US market ($USD651.40K).

Compensation vs Earnings: Garry's compensation has been consistent with company performance over the past year.

CEO

Garry Neil (70 yo)

2.8yrs

Tenure

US$1,075,362

Compensation

Dr. Garry A. Neil, M.D., serves as the Member of Scientific Advisory Board of Rapafusyn Research And Development, Inc. Dr. Garry serves as Independent Director of Celldex Therapeutics, Inc. since June 16,...

Leadership Team

NamePositionTenureCompensationOwnership
Garry Neil
Chairman of the Board2.8yrsUS$1.08m0.00057%
$ 525.5
Christopher Sullivan
CFO & Head of Investor relations2.8yrsUS$607.65k0.000060%
$ 55.3
Solomon Snyder
Founder and Chairman of Scientific Advisory Boardno datano datano data
Barbara Slusher
Founder and Member of Scientific Advisory Boardno datano datano data
Paul Varki
Chief Legal Officerless than a yearno datano data
Lisa Hegg
Senior Vice President of Program Management2.9yrsno datano data
Colleen Matkowski
Senior Vice President of Global Regulatory Affairs & Quality Assurance2.9yrsno datano data
Dino Miano
Senior Vice President of CMC & Technical Operations2.8yrsno datano data
Mittie Doyle
Chief Medical Officerless than a yearno datano data

2.8yrs

Average Tenure

59yo

Average Age

Experienced Management: AVTX's management team is considered experienced (2.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Garry Neil
Chairman of the Board2.5yrsUS$1.08m0.00057%
$ 525.5
Solomon Snyder
Founder and Chairman of Scientific Advisory Boardno datano datano data
Barbara Slusher
Founder and Member of Scientific Advisory Boardno datano datano data
Sol Barer
Special Advisor & Strategic Advisory Board3.5yrsUS$133.94kno data
Gilla Kaplan
Independent Director4.2yrsUS$60.12k0%
$ 0
Ronald Borchardt
Member of Scientific Advisory Boardno datano datano data
Robert Lenox
Member of Scientific Advisory Boardno datano datano data
Anne Young
Member of Scientific Advisory Boardno datano datano data
Dennis Liotta
Member of Scientific Advisory Boardno datano datano data
Aaron Kantoff
Independent Directorless than a yearno datano data
Samantha Truex
Independent Directorless than a yearno datano data
Mitchell Chan
Independent Director3yrsUS$60.12k0%
$ 0

2.8yrs

Average Tenure

70yo

Average Age

Experienced Board: AVTX's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 01:25
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Avalo Therapeutics, Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Julian HarrisonBTIG
Louise ChenCantor Fitzgerald & Co.
Raghuram SelvarajuH.C. Wainwright & Co.